Panbela Therapeutics Inc. (PBLA)
(Delayed Data from OTC)
$0.35 USD
-0.01 (-3.45%)
Updated Oct 4, 2024 03:09 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
PBLA 0.35 -0.01(-3.45%)
Will PBLA be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PBLA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PBLA
Panbela (PBLA) Up 11% on Update From Pancreatic Cancer Study
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug
PBLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Panbela (PBLA) Regains Flynpovi Rights to Treat FAP
Other News for PBLA
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
PBLA Stock Earnings: Panbela Therapeutics Beats EPS for Q2 2024
H.C. Wainwright Remains a Hold on Panbela Therapeutics (PBLA)
Panbela Therapeutics Inc (PBLA) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ...
Panbela Provides Business Update and Reports Q2 2024 Financial Results